Matches in SemOpenAlex for { <https://semopenalex.org/work/W1573627501> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W1573627501 startingPage "827" @default.
- W1573627501 abstract "Gastric cancer is a highly prevalent disease in Portugal with impact on morbidity and mortality. The approach to a stomach cancer depends on the disease status and prognosis at the time of diagnosis. Surgical resection is the only potentially curative treatment. Up to now, palliative chemotherapy has been the only advantageous therapy option for patients with unresectable advanced gastric cancer or after recurrence, with a median survival of six to nine months. Among the drugs with a known antitumor activity, 5-fluorouracil (5-FU) and cisplatin have been widely used in advanced gastric cancer, either in monotherapy, or in combination. However, 5-FU is administered by intravenous infusion, which requires the insertion of a central venous catheter or the patient's hospitalization and is therefore inconvenient and uncomfortable.Evaluation of the incremental cost in Portugal of using capecitabine as first line treatment in patients with advanced gastric carcinoma as an alternative to 5-FU, both used in association with cisplatin.The study was carried out using the Portuguese National Health Service (NHS) perspective, through an analysis of cost minimization, considering data from a phase III clinical study (ML17032) that demonstrates the non-inferiority of capecitabine versus 5-FU, both in association with cisplatin. A Markov model was developed to evaluate the treatment costs, using a cohort of patients with advanced gastric carcinoma and a timeframe of five cycles. This analysis considered only direct costs.The incremental cost analysis demonstrated savings of 5,868.60 euro per patient with capecitabine therapy (base scenario). The results obtained when considering alternative scenarios (sensitivity analysis), particularly that related to the 5-FU Administration method, reinforce the base scenario savings result.The analysis conducted demonstrated that the use of capecitabine+cisplatin (CAP-cis) allows a cost reduction when compared to the alternative 5-FU+cisplatin (5-FU-cis). Capecitabine clinical efficacy is not inferior to 5-FU and it has a more convenient and comfortable administration method. It also eliminates the risk of complications associated with intravenous perfusion, consequently reducing the need for hospitalisation. The replacement of 5-FU with capecitabine is shown to be economically advantageous." @default.
- W1573627501 created "2016-06-24" @default.
- W1573627501 creator A5036172775 @default.
- W1573627501 creator A5073570114 @default.
- W1573627501 creator A5081991766 @default.
- W1573627501 creator A5091098373 @default.
- W1573627501 date "2009-11-01" @default.
- W1573627501 modified "2023-09-25" @default.
- W1573627501 title "Economic evaluation of capecitabine use as first line treatment in patients with advanced gastric carcinoma in Portugal" @default.
- W1573627501 doi "https://doi.org/10.20344/amp.1727" @default.
- W1573627501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20350467" @default.
- W1573627501 hasPublicationYear "2009" @default.
- W1573627501 type Work @default.
- W1573627501 sameAs 1573627501 @default.
- W1573627501 citedByCount "3" @default.
- W1573627501 countsByYear W15736275012014 @default.
- W1573627501 countsByYear W15736275012017 @default.
- W1573627501 countsByYear W15736275012018 @default.
- W1573627501 crossrefType "journal-article" @default.
- W1573627501 hasAuthorship W1573627501A5036172775 @default.
- W1573627501 hasAuthorship W1573627501A5073570114 @default.
- W1573627501 hasAuthorship W1573627501A5081991766 @default.
- W1573627501 hasAuthorship W1573627501A5091098373 @default.
- W1573627501 hasConcept C121608353 @default.
- W1573627501 hasConcept C126322002 @default.
- W1573627501 hasConcept C141071460 @default.
- W1573627501 hasConcept C143998085 @default.
- W1573627501 hasConcept C2776694085 @default.
- W1573627501 hasConcept C2777909004 @default.
- W1573627501 hasConcept C2778239845 @default.
- W1573627501 hasConcept C2780456651 @default.
- W1573627501 hasConcept C526805850 @default.
- W1573627501 hasConcept C71924100 @default.
- W1573627501 hasConcept C72563966 @default.
- W1573627501 hasConceptScore W1573627501C121608353 @default.
- W1573627501 hasConceptScore W1573627501C126322002 @default.
- W1573627501 hasConceptScore W1573627501C141071460 @default.
- W1573627501 hasConceptScore W1573627501C143998085 @default.
- W1573627501 hasConceptScore W1573627501C2776694085 @default.
- W1573627501 hasConceptScore W1573627501C2777909004 @default.
- W1573627501 hasConceptScore W1573627501C2778239845 @default.
- W1573627501 hasConceptScore W1573627501C2780456651 @default.
- W1573627501 hasConceptScore W1573627501C526805850 @default.
- W1573627501 hasConceptScore W1573627501C71924100 @default.
- W1573627501 hasConceptScore W1573627501C72563966 @default.
- W1573627501 hasIssue "6" @default.
- W1573627501 hasLocation W15736275011 @default.
- W1573627501 hasLocation W15736275012 @default.
- W1573627501 hasOpenAccess W1573627501 @default.
- W1573627501 hasPrimaryLocation W15736275011 @default.
- W1573627501 hasRelatedWork W1538208486 @default.
- W1573627501 hasRelatedWork W1558570295 @default.
- W1573627501 hasRelatedWork W1985807041 @default.
- W1573627501 hasRelatedWork W2007441195 @default.
- W1573627501 hasRelatedWork W2014456971 @default.
- W1573627501 hasRelatedWork W2015477737 @default.
- W1573627501 hasRelatedWork W2024243282 @default.
- W1573627501 hasRelatedWork W2045415273 @default.
- W1573627501 hasRelatedWork W2068411507 @default.
- W1573627501 hasRelatedWork W2094417645 @default.
- W1573627501 hasRelatedWork W2118709435 @default.
- W1573627501 hasRelatedWork W2122434179 @default.
- W1573627501 hasRelatedWork W2145431191 @default.
- W1573627501 hasRelatedWork W2260362357 @default.
- W1573627501 hasRelatedWork W2284112170 @default.
- W1573627501 hasRelatedWork W2343654140 @default.
- W1573627501 hasRelatedWork W2419045199 @default.
- W1573627501 hasRelatedWork W2590707448 @default.
- W1573627501 hasRelatedWork W2626781146 @default.
- W1573627501 hasRelatedWork W2749713164 @default.
- W1573627501 hasVolume "22" @default.
- W1573627501 isParatext "false" @default.
- W1573627501 isRetracted "false" @default.
- W1573627501 magId "1573627501" @default.
- W1573627501 workType "article" @default.